Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Assessing Safety and Efficacy of Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis (The REPOSE Study)

NCT06315010 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT06315010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06315010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Assessing Safety and Efficacy of Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis (The REPOSE Study)
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Recruiting
Start date
June 27, 2025
Completion date
April 30, 2028
Enrollment
20 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, nsclc, ros1 gene rearrangement